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Dear editor 
Zika virus (ZIKV) is a member of the family Flaviviridae, which comprises 
mosquito-borne viruses that pose major public health threats, such as Dengue 
(DENV) and Yellow Fever (YFV). ZIKV infections in humans were first reported 
in 1952 (Nigeria), and since then have spread around the world. The virus has 
probably arrived in Brazil in early 2015, and has been associated with neurological 
symptoms, including microcephaly1. 
Here, we used the data concerning the DENV cases during the last years in Brazil2 
to infer about future ZIKV outbreaks. The possibility of infection by any DENV 
serotype creates an epidemiological profile where each outbreak corresponds to the 
circulation of a serotype in a non-exposed population. Unlike the DENV, ZIKV 
has only one serotype, although two ZIKV lineages (Asian and African) have been 
reported. Indeed, it has been shown that sera from mice infected with either African 
or Asian ZIKV lineages were capable of neutralizing equivalently homologous and 
heterologous ZIKV lineages3. Thus, one only ZIKV serotype may induce a different 
epidemiological scenario of DENV, with a longer time interval between outbreaks 
and explain its probable forthcoming epidemiology. In Brazil, for example, the arrival 
of ZIKV created a peak in the number of cases in a naïve population4. However, 
after the virus established itself in the population, we expected an increase in the 
number of people who develop immunity, causing a decrease in the number of cases 
(Figure 1A). Similar situation is likely to occur with Chikungunya virus (CHIKV) 
infection, an emergent single serotype alphavirus without vaccine available, which 
usually shows epidemiological silencing of 3-4 years5.
The decrease in the number of zika disease cases after the 8th Epidemiological 
Week (EW) of 2016 (February 21st to 27th), cannot yet be explained by herd 
immunity, but is probably due to vector seasonal features, as reported for dengue 
cases during the same time4,6. Therefore, despite the 130,759 confirmed cases of zika 
disease until the EW 4 (2017)7, it may still take some years before the herd immunity 
decreases the number of cases, which will remain lower until the emergence of a 
new naïve human generation, leading to a second outbreak (Figure 1A).
Under these circumstances, it is necessary to discuss proper measures to avoid a 
rise in ZIKV cases. In Brazil, environmental education and vector control were not able 
to contain DENV infections in the past decades, and did not prevent the emergence of 
other arboviruses transmitted by the same mosquito vector (e.g. ZIKV and CHIKV)8. 
Therefore, vaccination appears to be the best way to prevent new future 
ZIKV outbreaks (Figure 1B). Nevertheless, it is important to acknowledge that 
cross-reaction between DENV and ZIKV antibodies has been reported and sub-
neutralizing concentrations of antibodies to DENV or ZIKV could enhance the viral 
entry into cells and contribute to the pathogenesis; a phenomenon called antibody-
dependent enhancement (ADE)9,10.
This should be considered when analyzing the process of vaccination against 
dengue (already available)11 and zika (still under research and development 
process)12. A prudent way of thinking about vaccination and strategies for vaccine 
development for ZIKV and DENV, ensuring their simultaneous control would 
Silva Júnior et al.
Rev Inst Med Trop São Paulo. 2017;59:e21Page 2 of 2
be: i) synchronization of DENV and ZIKV vaccination 
calendars with a simultaneous immunization program; 
ii) production of a pentavalent vaccine (DENV 1-4 plus 
ZIKV); and iii) identification of DENV- and ZIKV- specific 
neutralizing epitopes to develop a safer vaccine and avoid 
the ADE risk.
Finally, knowing that herd immunity and ADE events 
play an important role concerning ZIKV infections, we 
believe that the future success in ZIKV control relies on 
the strengthening of the relationship between public health 
and molecular virology. 
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Figure 1 - Possible dynamics of zika disease before (A) and 
after (B) vaccination. For illustrate the probable epidemiological 
profile of the virus before and after vaccination, the figure 
was constructed from the concept of herd immunity and the 
existence of only one ZIKV serotype. The numbers of confirmed 
cases of zika disease were not used because the outbreak is 
still at the beginning and does not reflect the timeline described 
in the figure.
